Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform
Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and more
Expects ACT to contribute US$25-30 million in revenues in 2023
Positions Prenetics solidly within the US$80+ billion global precision oncology market
Acquisition expected to complete on or around December 30, 2022, subject to normal closing conditions
Prenetics Global Limited a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT Genomics Holdings Company Limited (
